Pathobionts in IBD: Origins, Underlying Mechanisms, and Implications for Clinical Care.

作者：A. Gilliland, Jocelyn J. Chan, T. D. De Wolfe, Hyungjun Yang, B. Vallance · 发表于：Gastroenterology · 年份：2023 · DOI：10.1053/j.gastro.2023.09.019 · 被引用次数：175 · 研究领域：Medicine

The gut microbiota plays a significant role in the pathogenesis of both forms of inflammatory bowel disease (IBD), namely Crohn's disease (CD) and ulcerative colitis (UC). While evidence suggests dysbiosis and loss of beneficial microbial species can exacerbate IBD, many new studies have identified microbes with pathogenic qualities, termed "pathobionts", within the intestines of patients with IBD. The concept of pathobionts initiating or driving the chronicity of IBD has largely focused on the putative aggravating role that adherent invasive Escherichia coli may play in CD. However, recent studies have identified additional bacterial and fungal pathobionts in patients with CD and UC. This review will highlight the characteristics of these pathobionts and their implications for IBD treatment. Beyond exploring the origins of pathobionts, we discuss those associated with specific clinical features and the potential mechanisms involved, such as creeping fat (Clostridium innocuum) and impaired wound healing (Debaryomyces hansenii) in patients with CD as well as the increased fecal proteolytic activity (Bacteroides vulgatus) seen as a biomarker for UC severity. Finally, we examine the potential impact of pathobionts on current IBD therapies, and several new approaches to target pathobionts currently in the early stages of development. Despite recognizing that pathobionts likely contribute to the pathogenesis of IBD, more work is needed to define their modes of action. Determining ...